Wang Michelle J, Bazan Maria, Hsieh Tina, Mita Carol, Ferrés Millie A, Oyelese Yinka
Department of Obstetrics & Gynecology, Division of Maternal Fetal Medicine, Beth Israel Deaconess Medical Center, Boston, MA (Wang, Bazan, Hsieh, Ferrés, and Oyelese).
Department of Obstetrics & Gynecology, Division of Maternal Fetal Medicine, Beth Israel Deaconess Medical Center, Boston, MA (Wang, Bazan, Hsieh, Ferrés, and Oyelese).
Am J Obstet Gynecol MFM. 2025 Jul;7(7):101704. doi: 10.1016/j.ajogmf.2025.101704. Epub 2025 May 17.
The aim of this systematic review and meta-analysis was to describe the perinatal outcomes and modifiers of antenatally diagnosed cystic hygroma (CH).
The PubMed, Embase and Web of Science Core Collection databases were searched from inception until March 18, 2024.
Full-text English-language observational cohort studies reporting any pregnancy and postnatal outcomes for fetuses with a CH diagnosed on prenatal ultrasound were included in this study.
The primary outcome was the incidence of genetic diagnosis and incidence of major structural anomalies. Secondary outcomes included the incidence of perinatal loss, termination of pregnancy, CH resolution, live birth rate and normal postnatal outcomes. Stratified analyses were conducted of cases diagnosed in the first trimester as well as all cases with septations as part of diagnostic criteria. Pooled proportions were calculated for the different outcomes.
Fifty-seven studies met inclusion criteria (including 4693 cases of CH); these were cohort studies that included any of our primary search outcomes. The pooled prevalence of genetic diagnosis (56 studies, 3837 fetuses) was 55% (95% CI, 0.51-0.58). For specific aneuploidies, the pooled prevalence was 21% for Turner syndrome, 17% for Trisomy 21, 10% for Trisomy 18, 3% for Trisomy 13, and 5% for other genetic diagnoses. The overall pooled prevalence of major structural anomalies (30 studies, 1987 fetuses) was 42%; across 16 studies (1815 fetuses), 16% of fetuses with CH and an additional structural abnormality had no identified genetic diagnosis. Furthermore, 20% of all CH regressed or resolved during the pregnancy. The findings from the studies that that defined CH by the presence of septations, as well as those focusing solely on first trimester CH were consistent with the overall outcomes.
Our findings confirm that while CHs have a strong association with common trisomies and Turner syndrome, there is a proportion of cases with nonaneuploidy genetic diagnoses. Forty percent of cases are also associated with other structural anomalies that may be able to be elicited with a detailed first trimester anatomic ultrasound. Further studies should explore modifiers of CH outcomes to allow for more accurate and tailored patient counseling.
本系统评价和荟萃分析的目的是描述产前诊断的颈部水囊瘤(CH)的围产期结局及相关影响因素。
检索了PubMed、Embase和Web of Science核心合集数据库,检索时间从建库至2024年3月18日。
纳入全文为英文的观察性队列研究,这些研究报告了产前超声诊断为CH的胎儿的任何妊娠和产后结局。
主要结局为基因诊断的发生率和主要结构异常的发生率。次要结局包括围产期丢失、终止妊娠、CH消退、活产率和正常产后结局的发生率。对孕早期诊断的病例以及所有将分隔作为诊断标准一部分的病例进行分层分析。计算不同结局的合并比例。
57项研究符合纳入标准(包括4693例CH病例);这些均为队列研究,涵盖了我们的任何一项主要检索结局。基因诊断的合并患病率(56项研究,3837例胎儿)为55%(95%CI,0.51 - 0.58)。对于特定的非整倍体,Turner综合征的合并患病率为21%,21三体综合征为17%,18三体综合征为10%,13三体综合征为3%,其他基因诊断为5%。主要结构异常的总体合并患病率(30项研究,1987例胎儿)为42%;在16项研究(1815例胎儿)中,16%患有CH且伴有其他结构异常的胎儿未明确基因诊断。此外,20%的所有CH在孕期消退或消失。根据是否存在分隔来定义CH的研究结果,以及仅关注孕早期CH的研究结果与总体结局一致。
我们的研究结果证实,虽然CH与常见的三体综合征和Turner综合征密切相关,但仍有一部分病例为非非整倍体基因诊断。40%的病例还与其他结构异常有关,这些异常可能通过详细的孕早期解剖超声检查发现。进一步的研究应探索CH结局的影响因素,以便为患者提供更准确、更具针对性的咨询。